Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

NICE to look at lowering blood pressure targets in guidance overhaul

NICE has given the green light for a full update of its guidance on hypertension – including the potential introduction of lower blood pressure targets that could see GPs treating many more people with antihypertensive drugs.

It comes despite recent RCGP advice for GPs to only treat hypertension if blood pressure is consistently above the current NICE-recommended threshold of 140/90 mmHg, as part of the Choosing Wisely campaign aimed at cutting down on unnecessary treatments.

Pulse previously revealed that NICE experts were considering new evidence on lowering blood pressure to a target of 120mmHg in high-risk patients, as part of a review of the current guidance published in 2011.

Having concluded the review, NICE has now announced that it will carry out a full update of the guidelines and confirmed to Pulse that this will consider new evidence on blood pressure targets as part of revisions to the guidelines section on ‘initiating and monitoring antihypertensive drug treatment, including blood pressure targets’.

The update will also take in new evidence on management of blood pressure in people with type 2 diabetes, previously covered in the condition-specific NICE guidelines on diabetes.

Dr Terry McCormack, secretary of the British Hypertension Society and a GP in Whitby, North Yorkshire, was involved in the reappraisal of the guidelines in his role as NICE topic expert advisor.

He told Pulse that the full update ‘will include targets, fourth line therapy, lifestyle and diabetes’ and that the review of blood pressure targets ‘will specifically evaluate SPRINT’.

But he noted it was unlikely to reduce the target to as low as 120mmHg and would likely included recommendations on more intensive drug treatment, and adherence. 

Dr McCormack said: ‘The actual achieved target was closer to 130mmHg. The average number of drugs in each arm were 2.8 and 1.8 which is more significant in my mind.’

He added: ‘They also stopped drugs in the “standard” treatment arm, mostly diuretics.’

As Pulse reported, the SPRINT trial was a large US study that reported that treating high-risk patients with hypertension to a systolic target of 120mmHg cut mortality and cardiovascular events, when compared with treatment to the usual 140mmHg goal.

At the time, GP cardiovascular experts said the trial could 'fundamentally change' GPs' practice, and academics who carried out a meta-analysis of new trials evidence including SPRINT have since called on NICE to introduce the lower target in guidelines.

Currently NICE recommends GP should offer antihypertensive treatment to people with stage 1 hypertension (140-159mmHg) if they have an additional risk factor such as existing heart disease or diabetes, and to aim for a target clinic blood pressure below 140/90 mmHg in those aged under 80 years.

A NICE spokesperson said: ‘A full scoping exercise will be carried out on this topic, so the exact recommendations to be updated will be identified during that process based primarily on the areas for update we identified during surveillance. One of those areas was initiating and monitoring which includes blood pressure targets.’

The guidelines update could also see the introduction of new recommendations on self-management, following evidence showing that getting patients to self-titrate their blood pressure medications can help high-risk groups improve control of their blood pressure.

Other areas that will be updated include lifestyle recommendations, with new evidence emerging for specific interventions, choice of antihypertensive – in particular, fourth-line options – and the optimal timing of treatment, after studies showed evening doses may improve patient outcomes.

NICE is also extending the scope of the guidelines to take in management of blood pressure in people with type 2 diabetes - previously considered under the condition specific guidance - and secondary care of malignant hypertension.

The RCGP declined to comment until the updated NICE guidance is published.

Emerging evidence on hypertension

SPRINT was a randomised controlled trial included more than 9,000 patients, typically aged around 70 and with at least one cardiovascular risk factor – but not diabetes – and an average baseline blood pressure of 139/78mmHg.

Results – unveiled provisionally last year and subsequently published in the New England Journal of Medicine – showed that, on average, patients who received an intensive treatment regimen got their systolic blood pressure down to around 121mmHg, compared with around 136mmHg in the standard treatment group.

Cardiovascular events or death were reduced 25% in the intensive treatment group compared with standard treatment.

GP experts previously told Pulse the new evidence could have ‘major implications’ for general practice.

However, the RCGP recently reinforced the current NICE target, calling for GPs to only treat hypertension in people with drugs if blood pressure is consistently above 140/90 mmHg and they have additional risk factors.

According to RCGP leads on Choosing Wisely, there is a tendency for people to be treated more aggressively than this owing to the legacy of earlier, lower targets - such as previous audit blood pressure levels in QOF that have now been retired. 

 

Readers' comments (22)

  • The only people who win will be the pharmaceutical companies.
    For doctors it will be more work.
    For patients more expense, anxiety and side effects damage to them.
    Pharma will be rubbings their hands with glee!

    Unsuitable or offensive? Report this comment

  • Will there ever come a time when target is set and doesn't change (for change sake)

    Unsuitable or offensive? Report this comment

  • 'So doc how many of these tablets should I be taking then??' 'Well according to the latest guidelines keep taking them until you fall over and then slightly reduce the dose that's the sweet spot right there'

    Unsuitable or offensive? Report this comment

  • Streets free I've style is more helpful in controlling blood pressure in mild hypertension than the chi idiot of anti hypertensive drugs. I would recommend practicing yoga and meditation in those who have mild hypertension!

    Unsuitable or offensive? Report this comment

  • No doubt the great and the good of NICE have looked into
    * the Kungsholmen project: Does dementia cause low blood pressure or does low blood pressure cause dementia?
    * falls and fractures
    * hypotension-linked MIs and ischaemic strokes in the elderly
    * the CardioBrief that gave thumbs down to SPRINT

    By the by, have all authors of the new recommendations signed disclosures related to pharma connections?

    Unsuitable or offensive? Report this comment

  • "SPRINT was a randomised controlled trial included more than 9,000 patients, typically aged around 70 and with at least one cardiovascular risk factor – but not diabetes – and an average baseline blood pressure of 139/78mmHg."
    So SPRINT was a trial in patients with co-morbidities: does this *necessarily+ mean that lowering BP to 120/60 in patients *without* additional risk factors (and under 50) would produce the same lowering of already low risk?
    And was the management of the other risk factors changed at the same time or by the introduction of additional medication to lower the BP?

    Unsuitable or offensive? Report this comment

  • For once I agree with the comments - more work for GPs when patients who are really ill struggle to see someone; more work for pharmacies supplying what may be unnecessary treatments; more cost to the NHS - although I am assuming there would have to be an overall cost saving to make it worth the effort; and last but by no means least, more expense & worry to patients. Oh, and lots more people living to a ripe old age to put MORE drain on the system. Does sometimes make me wonder what the final aim is? Let's all live forever! (Can't wait!)

    Unsuitable or offensive? Report this comment

  • This is a bit of a non-story. NICE are only quoted as saying 'they would consider new evidence'. This is their job to consider all evidence. Come on Pulse this story is a bit 'daily mail'.

    Unsuitable or offensive? Report this comment

  • This surely takes us in the opposite direction to the person-centred approach recommended in the recent NICE Multimorbidity guidance?

    Unsuitable or offensive? Report this comment

  • Vinci Ho

    Let's wait until NICE 's publication. It is never a one side story. Remember the history ; the row between BHS and NICE on ABCD anti-hypertensives?

    Unsuitable or offensive? Report this comment

View results 10 results per page20 results per page50 results per page

Have your say